View Featured Offers >>
PTMScan® HS Ubiquitin/SUMO Remnant Motif (K-ε-GG) Kit
Proteomic Analysis Products

PTMScan® HS Ubiquitin/SUMO Remnant Motif (K-ε-GG) Kit #59322

Reviews ()
Citations (0)
PTMScan® HS Ubiquitin/SUMO Remnant Motif (K-ε-GG) Kit: Image 1
Motif analysis using all ubiquitin remnant peptides enriched and identified by PTMScan® HS Ubiquitin/SUMO Remnant Motif (K-ε-GG) Kit from three different samples. One milligram each of mouse brain, mouse liver, and MKN-45 human gastric cancer cells were independently digested with trypsin and immunoprecipitated with PTMScan® HS K-ε-GG Remnant Magnetic Immunoaffinity Beads. Orbitrap Fusion Lumos mass spectrometer analysis identified a total of 8,928 non-redundant sites. The motif logo shows that the K-ε-GG antibody is a general motif antibody that recognizes the K-ε-GG motif independent of protein context, without other amino acid preferences.
Product Includes Volume (with Count)
PTMScan® HS K-ε-GG Remnant Magnetic Immunoaffinity Beads 1 x 200 µl
PTMScan® HS Immunoaffinity Purification (IAP) Bind Buffer #1 (1X) 1 x 25 ml
PTMScan® HS Immunoaffinity Purification (IAP) Wash Buffer (1X) 1 x 50 ml
PTMScan® Limited Use License 1 x 1 ea

Product Usage Information

Kit contains 10 assays.

Protocol for peptide enrichment can be found on the #59322 data sheet. Protocol for peptide sample preparation and additional reagents can be found on the companion kit data sheets #85106 and #98883.

Important for SUMO Remnant: Wild type alpha-lytic protease (WaLP) is a serine endopeptidase that cleaves at the carboxyl terminal side of amino acids alanine, serine, threonine, and valine. Please check that the predicted SUMO sequence of your model organism contains AGG, SGG, TGG or VGG at the c-terminus to ensure reactivity.


All components in this kit are stable for at least 12 months when stored at the recommended temperature. Do not aliquot the antibody.

Product Description

PTMScan® HS is an enhanced PTMScan® methodology with improved identification of post-translationally modified peptides. PTMScan® technology employs a proprietary methodology from Cell Signaling Technology (CST) for peptide enrichment by immunoprecipitation using a specific bead-conjugated antibody in conjunction with liquid chromatography tandem mass spectrometry (LC-MS/MS) for quantitative profiling of post-translational modification (PTM) sites in cellular proteins. PTMs that can be analyzed by PTMScan® technology include phosphorylation, ubiquitination, acetylation, and methylation, among others. The technology enables researchers to isolate, identify, and quantitate large numbers of post-translationally modified cellular peptides with a high degree of specificity and sensitivity (HS), providing a global overview of PTMs in cell and tissue samples without bias about where the modified sites occur. For more information on PTMScan® products and services, please visit Proteomics Resource Center.


Ubiquitin is a conserved polypeptide unit that plays an important role in the ubiquitin-proteasome pathway. Ubiquitin can be covalently linked to many cellular proteins by the ubiquitination process, which targets proteins for degradation by the 26S proteasome. Three components are involved in the target protein-ubiquitin conjugation process. Ubiquitin is first activated by forming a thiolester complex with the activation component E1; the activated ubiquitin is subsequently transferred to the ubiquitin-carrier protein E2, then from E2 to ubiquitin ligase E3 for final delivery to the epsilon-NH2 of the target protein lysine residue (1-3). The ubiquitin-proteasome pathway has been implicated in a wide range of normal biological processes and in disease-related abnormalities. Several proteins such as IκB, p53, cdc25A, and Bcl-2 have been shown to be targets for the ubiquitin-proteasome process as part of regulation of cell cycle progression, differentiation, cell stress response, and apoptosis (4-7).

Small ubiquitin-related modifier 1, 2, and 3 (SUMO-1, -2, and -3) are members of the ubiquitin-like protein family (8). The covalent attachment of the SUMO-1, -2, or -3 (SUMOylation) to target proteins is analogous to ubiquitination.

Ubiquitin and the individual SUMO family members are all targeted to different proteins with diverse biological functions. Ubiquitin predominantly regulates degradation of its target (8). In contrast, SUMO-1 is conjugated to RanGAP, PML, p53, and IκB-α, regulates nuclear trafficking, forms subnuclear structures, and regulates transcriptional activity and protein stability (9-13). SUMO-2/-3 forms poly-(SUMO) chains, is conjugated to topoisomerase II and APP, regulates chromosomal segregation and cellular responses to environmental stress, and plays a role in the progression of Alzheimer's disease (14-17).
  1. Ciechanover, A. (1998) EMBO J 17, 7151-60.
  2. Hochstrasser, M. (2000) Nat Cell Biol 2, E153-7.
  3. Hochstrasser, M. (2000) Science 289, 563-4.
  4. Bernardi, R. et al. (2000) Oncogene 19, 2447-54.
  5. Aberle, H. et al. (1997) EMBO J 16, 3797-804.
  6. Salomoni, P. and Pandolfi, P.P. (2002) Nat Cell Biol 4, E152-3.
  7. Jesenberger, V. and Jentsch, S. (2002) Nat Rev Mol Cell Biol 3, 112-21.
  8. Schwartz, D.C. and Hochstrasser, M. (2003) Trends Biochem. Sci. 28, 321-8.
  9. Matunis, M.J. et al. (1996) J. Cell Biol. 135, 1457-70.
  10. Duprez, E. et al. (1999) J. Cell Sci. 112, 381-93.
  11. Gostissa, M. et al. (1999) EMBO J. 18, 6462-74.
  12. Rodriguez, M.S. et al. (1999) EMBO J. 18, 6455-61.
  13. Desterro, J.M. et al. (1998) Mol. Cell 2, 233-9.
  14. Tatham, M.H. et al. (2001) J. Biol. Chem. 276, 35368-74.
  15. Azuma, Y. et al. (2003) J. Cell Biol. 163, 477-87.
  16. Li, Y. et al. (2003) Proc. Natl. Acad. Sci. USA 100, 259-64.
  17. Saitoh, H. and Hinchey, J. (2000) J. Biol. Chem. 275, 6252-8.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PTMScan is a trademark of Cell Signaling Technology, Inc.
Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at [email protected] For information regarding commercial licensing terms please contact CST Pharma Services Department at [email protected]
All other trademarks are the property of their respective owners. Visit our Trademark Information page.